Johnson & Johnson $JNJ Shares Sold by Sowell Financial Services LLC

Sowell Financial Services LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% during the 3rd quarter, Holdings Channel reports. The firm owned 55,176 shares of the company’s stock after selling 2,062 shares during the period. Sowell Financial Services LLC’s holdings in Johnson & Johnson were worth $14,607,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. One Wealth Capital Management LLC increased its holdings in shares of Johnson & Johnson by 511.0% during the 3rd quarter. One Wealth Capital Management LLC now owns 5,010 shares of the company’s stock worth $1,326,000 after acquiring an additional 4,190 shares during the last quarter. Lorne Steinberg Wealth Management Inc. raised its stake in Johnson & Johnson by 2.1% in the 3rd quarter. Lorne Steinberg Wealth Management Inc. now owns 39,472 shares of the company’s stock valued at $10,450,000 after acquiring an additional 795 shares during the period. Evergreen Capital Management LLC lifted its holdings in Johnson & Johnson by 2.3% during the 3rd quarter. Evergreen Capital Management LLC now owns 67,727 shares of the company’s stock valued at $17,930,000 after purchasing an additional 1,502 shares during the last quarter. Altura Wealth Advisors Inc. lifted its holdings in Johnson & Johnson by 13.1% during the 3rd quarter. Altura Wealth Advisors Inc. now owns 8,541 shares of the company’s stock valued at $2,261,000 after purchasing an additional 988 shares during the last quarter. Finally, RWC Asset Management LLP lifted its holdings in Johnson & Johnson by 2.1% during the 3rd quarter. RWC Asset Management LLP now owns 267,730 shares of the company’s stock valued at $70,879,000 after purchasing an additional 5,591 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on JNJ. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Freedom Capital upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Tuesday, September 29th. UBS Group set a $270.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 14th. Finally, HSBC increased their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 64,515 shares of company stock worth $17,271,766. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.9%

JNJ stock opened at $271.17 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The stock has a market capitalization of $652.78 billion, a price-to-earnings ratio of 41.09, a PEG ratio of 2.61 and a beta of 0.21. The business’s fifty day moving average price is $265.60 and its two-hundred day moving average price is $246.26. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter in the previous year, the business posted $2.80 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s payout ratio is 81.21%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ is included among pharmaceutical companies with potential arthritis-treatment growth, supported by drug sales, clinical progress and regulatory expansion. This reinforces the outlook for its Innovative Medicine business and future cash generation. The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
• Positive Sentiment: The company will hold an Enterprise Business Review on December 8, when management is expected to provide additional detail on its Innovative Medicine and MedTech pipelines, long-term strategy and growth opportunities. The event could offer catalysts if the company raises confidence in future earnings. Johnson & Johnson to Host Enterprise Business Review
• Neutral Sentiment: JNJ has gained roughly 97% over three years, prompting investors to assess whether its valuation is supported by expected cash flow. Oncology trial developments and MedTech performance could materially influence that assessment. Johnson & Johnson Stock Trades At A Discount Following Its 97% Run
• Negative Sentiment: Ongoing attention to a talc-related charge adds legal and cash-flow uncertainty, while investors continue to monitor the broader talc litigation overhang. What Does the Talc Charge Mean for Johnson & Johnson Going Forward?
• Negative Sentiment: Reports of approximately $34.7 million in net ETF selling represent a modest technical headwind, although such flows do not necessarily reflect a change in JNJ’s fundamentals. Johnson & Johnson Sees $34.7 Million in Net ETF Selling
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of JNJ investors. The announcement does not establish wrongdoing, but it adds to headline and litigation risk. Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Johnson & Johnson

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.